Literature DB >> 11221997

Monoclonal antibodies derived from BALB/c mice immunized with apoptotic Jurkat T cells recognize known autoantigens.

T J Gensler1, M Hottelet, C Zhang, S Schlossman, P Anderson, P J Utz.   

Abstract

It has been postulated that post-translational modifications and relocalization of proteins during apoptosis may lead to presentation of these molecules to the immune system in such a way that normal mechanisms of tolerance are bypassed. In the present study, Jurkat cells were induced to undergo apoptosis by treatment with the chemotherapeutic agent Ara-C. BALB/c mice were then immunized with the apoptotic cells and hybridomas were generated. Using an indirect immunofluorescence assay, the monoclonal antibodies produced were screened by flow cytometry for those monoclonal antibodies demonstrating reactivity with permeabilized apoptotic Jurkat cells but not with non-permeabilized normal or apoptotic Jurkat cells. Of 281 monoclonal antibodies, 20 monoclonal antibodies with these properties were selected for further analysis. Using 32P- or 35S-metabolically labelled Jurkat cells, these selected monoclonal antibodies were screened for their ability to recognize autoantigens by immunoprecipitation and Western blotting. Well characterized autoimmune sera were then used to confirm the identity of autoantigens by immunoblotting. We demonstrate that immunization of normal mice with apoptotic Jurkat cells results in the formation of antibodies targeting multiple autoantigens or autoantigen complexes, including Ku, rRNPs, snRNPs and vimentin. These findings are consistent with the hypothesis that apoptosis can contribute to the development of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221997     DOI: 10.1006/jaut.2000.0464

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  Improving seroreactivity-based detection of glioma.

Authors:  Nicole Ludwig; Andreas Keller; Sabrina Heisel; Petra Leidinger; Veronika Klein; Stefanie Rheinheimer; Claudia U Andres; Bernhard Stephan; Wolf-Ingo Steudel; Norbert M Graf; Bernhard Burgeth; Joachim Weickert; Hans-Peter Lenhof; Eckart Meese
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 2.  Autoantigenesis: the evolution of protein modifications in autoimmune disease.

Authors:  Hester A Doyle; Mark J Mamula
Journal:  Curr Opin Immunol       Date:  2011-12-29       Impact factor: 7.486

3.  Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Authors:  Y Yang; J Fujita; S Bandoh; Y Ohtsuki; I Yamadori; T Yoshinouchi; T Ishida
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 4.  Apoptosis and autoimmunity.

Authors:  Jeannine S Navratil; Chau-Ching Liu; Joseph M Ahearn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Apoptosis as a mechanism for cell surface expression of the autoantigen pyruvate dehydrogenase complex.

Authors:  P Macdonald; J Palmer; J A Kirby; D E J Jones
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

6.  Development of autoimmunity in mice lacking DNA topoisomerase 3beta.

Authors:  Kelvin Y Kwan; Rebecca J Greenwald; Subhasis Mohanty; Arlene H Sharpe; Albert C Shaw; James C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

7.  Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies.

Authors:  Chih Long Liu; Stephanie Tangsombatvisit; Jacob M Rosenberg; Gil Mandelbaum; Emily C Gillespie; Or P Gozani; Ash A Alizadeh; Paul J Utz
Journal:  Arthritis Res Ther       Date:  2012-02-02       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.